Ichnos Glenmark Innovation Inc.
Ichnos Glenmark Innovation (IGI) Announces IND Submission to U.S. FDA for ISB 2301, a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors
ISB 2301 targets three tumor-associated antigens (TAAs) and engages both T cells and natural killer (NK) cells IGI plans to initiate a Phase 1 trial…
